Get the Stockscreener App
1.44
1.37%
-0.02
Gain Therapeutics Inc stock is traded at $1.44, with a volume of 246.31K.
It is down -1.37% in the last 24 hours and down -8.28% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$1.46
Open:
$1.46
24h Volume:
246.31K
Relative Volume:
0.86
Market Cap:
$43.30M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-1.3091
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
-14.79%
1M Performance:
-8.28%
6M Performance:
-32.39%
1Y Performance:
+35.85%
1-Day Range:
$1.41
$1.52
1-Week Range:
$1.41
$1.69
52-Week Range:
$0.89
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.44 | 50.47M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
Evaluating Gain Therapeutics Inc. with trendline analysisConsistent Return Setup with Exit Strategy - Newser
Using flow based indicators on Gain Therapeutics Inc.Annual Market Behavior and Sector Summary - Newser
What are the latest earnings results for Gain Therapeutics Inc.Top Growth Review With High Returns - jammulinksnews.com
What is the risk reward ratio of investing in Gain Therapeutics Inc. stockMarket Forecast Updates That Work - jammulinksnews.com
Why Gain Therapeutics Inc. stock attracts strong analyst attentionLong-Term Allocation Strategy Summary Breakdown - Newser
What makes Gain Therapeutics Inc. stock price move sharplyFree Real-Time Analysis With Entry Targets - Newser
RSI Reset May Fuel Rebound in Gain Therapeutics Inc.Smart Allocation Stock Pick Insights Gaining Interest - metal.it
Fibonacci Retracement Aligns with Support in Gain Therapeutics Inc.Market Surge Signal for Swing Traders Triggered - metal.it
What analysts say about Gain Therapeutics Inc. stock outlookSmart Swing Picks with Confirmed Signals - Newser
What are analysts’ price targets for Gain Therapeutics Inc. in the next 12 monthsFinancial News Planner For Consistent Profits - jammulinksnews.com
Published on: 2025-07-28 18:37:30 - metal.it
Is it the right time to buy Gain Therapeutics Inc. stockOverwhelming profit margins - jammulinksnews.com
How Resilient Is Gain Therapeutics Inc. Stock During Economic DownturnsPattern Recognition Tool for ROI Investors - Newser
Why is Gain Therapeutics Inc. stock attracting strong analyst attentionCapitalize on stocks with high profit margins - jammulinksnews.com
Candlestick signals on Gain Therapeutics Inc. stock today Watchlist Summary for Active Day Traders - Newser
What analysts say about Gain Therapeutics Inc. stock outlook Short-Term Upside Breakout Forecast System - Newser
What is the dividend policy of Gain Therapeutics Inc. stockUnmatched profit potential - jammulinksnews.com
What catalysts could drive Gain Therapeutics Inc. stock higher in 2025Skyrocketing profit margins - jammulinksnews.com
Should I hold or sell Gain Therapeutics Inc. stock in 2025High-velocity gains - jammulinksnews.com
Sectors Driving Future Growth for Gain Therapeutics Inc. StockLow Risk Consistent Winners - Newser
What analysts say about Gain Therapeutics Inc. stockHigh-yield growth strategies - PrintWeekIndia
Gain Therapeutics Inc. Stock Analysis and ForecastOutstanding risk-reward balance - PrintWeekIndia
Is Gain Therapeutics Inc. a good long term investmentOutstanding capital returns - Autocar Professional
What makes Gain Therapeutics Inc. stock attractive to long term investorsExplosive market performance - jammulinksnews.com
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference - The Manila Times
Gain Therapeutics to Present at BTIG's Annual Biotechnology Conference. - AInvest
Gain Therapeutics Leadership Team Set for Exclusive Fireside Chat at BTIG Annual Biotech Conference - Stock Titan
Is Indaptus Therapeutics Inc. a good long term investmentRapid market gains - jammulinksnews.com
What drives Gain Therapeutics Inc. stock priceUnbelievable profit margins - jammulinksnews.com
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):